FNDR website description (accessed 10/12/2022 and 10/8/2021): An inhalation peptide drug candidate (NF1001/PM181108) in partnership with National Centre of Oceanic and Antarctic Research (NCAOR) Goa, for Rx of MDR/XDR TB: We have a natural product derived peptide antibiotic with excellent in vitro and in vivo activity in mouse and guinea pig TB infection models. Peptide candidate kills TB through a novel mode of action by inhibiting ribosome associated GTPase activity blocking protein translation. Several in vivo, inhalation combination studies with Isoniazid and Rifampicin or second line drugs revealed superiority of peptide containing combinations. It reduced bacterial load in mouse lung tissue infected with drug resistant Mtb to below LOD in 1 month in combination with amikacin, moxifloxacin, ethambutol and pyrazinamide as compared to 3 months required for this combination without peptide antibiotic. Thus, this peptide has significant potential for treatment of MDR TB, shortening duration of therapy and sterilization. The drug candidate is at a stage of GLP toxicology preceding to filling IND."